Biogen (NASDAQ:BIIB) Given New $213.00 Price Target at Royal Bank Of Canada

Biogen (NASDAQ:BIIB) had its price target dropped by research analysts at Royal Bank Of Canada from $233.00 to $213.00 in a research report issued to clients and investors on Tuesday,MarketScreener reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price objective suggests a potential upside of 23.27% from the company’s current price.

A number of other analysts have also recently issued reports on the company. Sanford C. Bernstein reissued a “market perform” rating on shares of Biogen in a research report on Monday, February 9th. TD Cowen lifted their price objective on Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Canaccord Genuity Group raised their target price on Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a report on Wednesday, April 1st. Truist Financial lifted their price objective on Biogen from $190.00 to $193.00 and gave the stock a “hold” rating in a research note on Monday, February 9th. Finally, Wolfe Research set a $231.00 target price on Biogen in a report on Monday, February 9th. Twelve investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $207.54.

Biogen Stock Performance

Shares of Biogen stock opened at $172.79 on Tuesday. The stock has a market cap of $25.36 billion, a PE ratio of 19.47, a price-to-earnings-growth ratio of 2.37 and a beta of 0.16. Biogen has a 12 month low of $110.04 and a 12 month high of $202.41. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The business has a fifty day simple moving average of $186.58 and a 200-day simple moving average of $171.93.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business’s revenue for the quarter was down 7.2% on a year-over-year basis. During the same quarter last year, the firm earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, sell-side analysts anticipate that Biogen will post 15.83 EPS for the current fiscal year.

Insider Activity at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.18% of the company’s stock.

Institutional Trading of Biogen

Large investors have recently made changes to their positions in the company. Reflection Asset Management bought a new stake in shares of Biogen in the 4th quarter valued at $25,000. WPG Advisers LLC boosted its stake in Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares during the period. First Horizon Corp acquired a new position in shares of Biogen during the 4th quarter worth about $30,000. Root Financial Partners LLC boosted its stake in shares of Biogen by 198.4% during the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after buying an additional 123 shares during the last quarter. Finally, MV Capital Management Inc. acquired a new position in shares of Biogen during the 4th quarter worth about $34,000. Institutional investors own 87.93% of the company’s stock.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen announced a multi-target collaboration and license with Alloy Therapeutics to use Alloy’s AntiClastic™ antisense oligonucleotide (ASO) platform, giving Biogen access to RNA-targeting capabilities that can expand its early-stage pipeline and long-term growth optionality. Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform
• Neutral Sentiment: RBC trimmed its price target on BIIB to $213 but kept an Outperform rating, signalling continued analyst confidence in the company’s prospects while slightly lowering near-term upside expectations. Biogen (BIIB) Partners With Alloy Therapeutics on Antisense Drug Platform
• Neutral Sentiment: Broader health-care sector softness weighed on sentiment, contributing to downward pressure across names including Biogen despite company-specific pipeline news. Sector Update: Health Care Stocks Softer Late Afternoon
• Negative Sentiment: Biogen disclosed that first‑quarter results will include an acquired in‑process R&D, upfront and milestone expense of $34M (pre‑tax), and commentary indicates Q1 expenses will be notably higher than previously expected — a near-term earnings headwind that prompted investor selling. Biogen Expects 1Q Results Will Include Acquired In-Process R&D, Upfront and Milestone Expense of $34M on Pre-Tax Basis
• Negative Sentiment: Deal activity tied to Biogen (reports about the company’s recent acquisitions/agreements) is boosting targets’ shares (e.g., Apellis) but signals near-term cash outlays and integration risk for Biogen, which investors are treating as a short-term negative for margins and free cash flow. Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here’s What Shareholders Get

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.